Form 4: 89bio Director Steven Altschuler Acquires Stock Options

Director Steven Altschuler of 89bio, Inc. reports the acquisition of stock options for 56,400 shares of common stock.

Summary

• Steven Altschuler, a director of 89bio, Inc., filed a Form 4 with the SEC.
• The report details the acquisition of stock options representing the right to purchase 56,400 shares of 89bio's common stock.
• The options were granted on February 3, 2025, with an exercise price of $9.60.
• The options will vest in full on February 1, 2026, contingent upon Altschuler's continued service to the company.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants, which is neither particularly positive nor negative on its own.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates a grant of stock options to a director, which is a common form of executive compensation.

Stakeholder Impact

• The granting of stock options to a director aligns their interests with those of the shareholders, potentially incentivizing them to work towards increasing the company's value.

Key Dates